Transcriptomics based identification of S100A3 as the key anti-hepatitis B virus factor of 16F16

• Published in: Biomedicine & pharmacotherapy Vol. 163; p. 114904
• Main Authors: Mahmood, Faisal, Xu, Ruixian, Awan, Maher Un Nisa, Jia, Ting, Zhang, Taoping, Shi, Wengang, Liu, Min, Han, Qinqin, Zhu, Qianhua, Zhang, Qilin, Song, Yuzhu, Xia, Xueshan, Zhang, Jinyang
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.07.2023; Elsevier
• Subjects: 16F16; Animals; Antiviral activity; Antiviral Agents - pharmacology; Carcinoma, Hepatocellular; DNA, Viral - genetics; Gene Expression Profiling; Hep G2 Cells - metabolism; Hep G2 Cells - virology; Hepatitis B e Antigens; Hepatitis B Surface Antigens - genetics; Hepatitis B virus; Hepatitis B, Chronic - drug therapy; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; S100A3; Transcriptome; Transcriptomics; H-score; PBS; NAs; DMSO; HCC; 16F16; HPV; DEGs; shRNA; Transcriptomics; FBS; Antiviral activity; KEGG; Hepatitis B virus; S100A3; HBV; PGS; RT-qPCR; DAMP; HBX; HTAs; WHO
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114904

More than 250 million people worldwide have chronic hepatitis B virus (HBV) infections, resulting in over 1 million annual fatalities because HBV cannot be adequately treated with current antivirals. Hepatocellular carcinoma (HCC) risk is elevated in the presence of the HBV. Novel and powerful medications that specifically target the persistent viral components are needed to remove infection. This study aimed to use HepG2.2.15 cells and the rAAV-HBV1.3 C57BL/6 mouse model established in our laboratory to examine the effects of 16F16 on HBV. The transcriptome analysis of the samples was performed to examine the impact of 16F16 therapy on host factors. We found that the HBsAg and HBeAg levels significantly decreased in a dose-dependent manner following the 16F16 treatment. 16F16 also showed significant anti-hepatitis B effects in vivo. The transcriptome analysis showed that 16F16 regulated the expression of several proteins in HBV-producing HepG2.2.15 cells. As one of the differentially expressed genes, the role of S100A3 in the anti-hepatitis B process of 16F16 was further investigated. The expression of the S100A3 protein significantly decreased following the 16F16 therapy. And upregulation of S100A3 caused an upregulation of HBV DNA, HBsAg, and HBeAg in HepG2.2.15 cells. Similarly, knockdown of S100A3 significantly reduced the levels of HBsAg, HBeAg, and HBV DNA. Our findings proved that S100A3 might be a new target for combating HBV pathogenesis. 16F16 can target several proteins involved in HBV pathogenesis, and may be a promising drug precursor molecule for the treatment of HBV. [Display omitted] •16F16 significantly decreased the HBsAg and HBeAg secretions and HBV genome both in-vitro and in-vivo.•Transcriptomics analysis unveiled S100A3 as a new target for 16F16 in HBV treatment.•16F16 down regulates S100A3 activity, making it a great interest as potential antiviral target.